EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
出版年份 2013 全文链接
标题
EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 14, Issue 14, Pages 1765-1777
出版商
Future Medicine Ltd
发表日期
2013-11-06
DOI
10.2217/pgs.13.177
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
- (2015) Rodrigo Dienstmann et al. Oncotarget
- Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy
- (2013) RA Mello et al. Clinics
- Novel therapeutic targets in non-small cell lung cancer
- (2013) Muhammad Alamgeer et al. CURRENT OPINION IN PHARMACOLOGY
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
- (2013) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)
- (2013) Vera Hirsh et al. Journal of Thoracic Oncology
- The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer
- (2013) Ramon Andrade de Mello et al. PLoS One
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
- (2012) María José Méndez-Vidal et al. CANCER AND METASTASIS REVIEWS
- Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
- (2012) CE Bacchi et al. Clinics
- Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices
- (2012) RA Mello et al. Clinics
- Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
- (2012) S. A. Kono et al. CURRENT CANCER DRUG TARGETS
- Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
- (2012) Cesare Gridelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- (2012) Maurice Pérol et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor
- (2012) Satsuki Mochizuki et al. JNCI-Journal of the National Cancer Institute
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
- (2012) Alexander Drilon et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Pharmacogenetics ofEGFRin lung cancer: perspectives and clinical applications
- (2012) Clara Mayo et al. PHARMACOGENOMICS
- Feedback within the Inter-Cellular Communication and Tumorigenesis in Carcinomas
- (2012) Felix Rückert et al. PLoS One
- Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus
- (2012) Michael A. James et al. PLoS One
- Personalizando a medicina – estratégias para implementar a avaliação do rearranjo do ‘anaplastic lymphoma kinase’ no carcinoma do pulmão de não pequenas células em Portugal
- (2012) A. Araújo et al. Revista Portuguesa de Pneumologia
- EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
- (2012) Ramon Andrade de Mello et al. TUMOR BIOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting p53 to mitochondria for cancer therapy
- (2011) Lorenzo Galluzzi et al. CELL CYCLE
- Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy
- (2011) Y. Li et al. CLINICAL CANCER RESEARCH
- CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism
- (2011) Qiang Nie et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407
- (2011) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
- (2011) Radj Gervais et al. LUNG CANCER
- Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
- (2011) Ramon Andrade de Mello et al. Recent Patents on Anti-Cancer Drug Discovery
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
- (2010) J. S. W. Lind et al. CLINICAL CANCER RESEARCH
- The association of telomere length and genetic variation in telomere biology genesa
- (2010) Lisa Mirabello et al. HUMAN MUTATION
- Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
- (2010) Suzanne E. Dahlberg et al. JOURNAL OF CLINICAL ONCOLOGY
- The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
- (2010) Satoshi Shimizu et al. JOURNAL OF HEPATOLOGY
- Unlocking the Biological Clues of Lung Cancer
- (2010) Nasser Hanna Journal of Thoracic Oncology
- The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition
- (2010) Jean-Paul Sculier et al. Journal of Thoracic Oncology
- Clinical Features of Bronchioloalveolar Carcinoma with New Histologic and Staging Definitions
- (2010) Jon O. Ebbert et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of the Angiopoietins in vascular morphogenesis
- (2009) Markus Thomas et al. ANGIOGENESIS
- The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung
- (2009) S. Zienolddiny et al. CARCINOGENESIS
- Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
- (2009) Tsvetelina Pentcheva-Hoang et al. IMMUNOLOGICAL REVIEWS
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients
- (2009) Magdalena Bieniasz et al. LUNG CANCER
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
- (2009) Etienne Meylan et al. NATURE
- Are RAS mutations predictive markers of resistance to standard chemotherapy?
- (2009) Yohann Loriot et al. Nature Reviews Clinical Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer
- (2008) Hiroyuki Mano CANCER SCIENCE
- Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
- (2008) Stuart Thomson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer
- (2008) C. Behrens et al. CLINICAL CANCER RESEARCH
- KRAS mutations predict response to EGFR inhibitors
- (2008) Mitch Raponi et al. CURRENT OPINION IN PHARMACOLOGY
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- (2008) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma
- (2008) Chiara Gabellini et al. JOURNAL OF NEUROCHEMISTRY
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma
- (2008) Jenifer L. Marks et al. Journal of Thoracic Oncology
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More